振東製藥(300158.SZ)半年度淨利潤升15.20%至1.06億元
格隆匯8月15日丨振東製藥(300158.SZ)發佈2019年半年度報告,實現營業收入19.73億元,同比增長21.75%;歸屬於上市公司股東的淨利潤1.06億元,同比增長15.20%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤1.06億元,同比增長23.03%;基本每股收益0.1035元。
腫瘤、泌尿、補益三條重點管線
補益管線:以遍佈全國的朗迪鈣為核心,以點帶面,帶動振東製藥118個差異化OTC產品,形成獨具特色的OTC市場。
腫瘤管線:以複方苦蔘注射液多年來在市場上的聲譽和專家心目中的形象、多年的科研地位和學術能力,形成了健康的營銷網絡和腫瘤專家學術網絡。以其產生的效果和優勢來帶動發展扶正固本顆粒、西黃丸、消癌平片、注射用香菇多糖、注射用培美曲塞二鈉等第二梯隊的腫瘤產品。
泌尿管線:核心品種比卡魯胺膠囊快速發展,公司繼續拓寬銷售渠道,積極探索院外銷售,大幅提高增長業績。
公司繼續堅持以“腫瘤”、“泌尿”、“補益”三條管線為主,形成專業化研發佈局。
腫瘤管線:加大現有產品的深度研究和二次開發,在此基礎上不斷創新,全力推進在研和創新藥拉洛他賽脂質體項目。
泌尿管線:加快比卡魯胺膠囊的一致性評價,加大比卡魯胺膠囊的深度研究,繼續推進阿比特龍、恩雜魯胺、米拉貝隆等後續潛在品種的開發。
補益管線:以朗迪鈣為主,加快多維多礦、氨糖肽膠囊、PS+DHA、鈣維生素D3維生素K2咀嚼片等後續管線品種的研發進度。
在上述三條主要管線的基礎上,以現有的心腦血管、消化系統、抗感染類等管線為輔,形成傘形支撐點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.